The Optical Coherence Tomography Substudy Committee and the NORDIC Idiopathic Intracranial Hypertension Study Group* Purpose: To assess treatment efficacy using spectral-domain (SD) optical coherence tomography (OCT) measurements of papilledema in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), which evaluated the effects of acetazolamide and weight management and of placebo and weight management in eyes with mild visual loss.
3 vs. 2.1 mm 3 ; P ¼ 0.001). The RNFL thickness (P ¼ 0.01), TRT (P ¼ 0.003), and ONH volume (P ¼ 0.002) measurements also showed smaller increases in subjects who lost 6% or more of study entry weight. The acetazolamide (3.6 mm) and placebo (2.1 mm) groups showed minor RGCL thinning (P ¼ 0.06). The RNFL thickness, TRT, and ONH volume measurements showed moderate correlations (r ¼ 0.48e0.59; P 0.0001) with Frisén grade. The 14 eyes with RGCL thickness less than the fifth percentile of controls had worse PMD (P ¼ 0.001) than study eyes with RGCL in the fifth percentile or more.
Conclusions: In IIH, acetazolamide and weight loss effectively improve RNFL thickness, TRT, and ONH volume swelling measurements resulting from papilledema. In contrast to the strong correlation at baseline, OCT measures at 6 months show only moderate correlations with papilledema grade. Ophthalmology 2015; 122:1939 -1945 ª 2015 by the American Academy of Ophthalmology. *Supplemental material is available at www.aaojournal.org.
Spectral-domain (SD) optical coherence tomography (OCT)
has provided high-quality data collected from multiple clinical sites from patients naïve to treatment for papilledema resulting from idiopathic intracranial hypertension (IIH) who have mild vision loss at entry into the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). 1, 2 Optical coherence tomography reliably and reproducibly demonstrates alterations in the optic nerve head (ONH) and retinal layers (RNFLs) in patients with IIH. At baseline, we measured the average peripapillary RNFL thickness, average peripapillary total retina thickness (TRT), ONH volume, and the retinal ganglion cell layer (RGCL) plus inner plexiform layer (IPL) thickness in the macular region. The RNFL thickness, TRT, and ONH volume also correlated strongly with Frisén papilledema grade. 3 Prior studies of eyes with significant ONH swelling showed that 2-dimensional (2-D) segmentation analysis failures are common when using the proprietary OCT algorithms for measuring the effects of swelling in the peripapillary retina via RNFL thickness with SD OCT (Mandel G, et al. IOVS 2010; 51 :ARVO E-Abstract 555) and TRT with timedomain OCT. 4 For eyes studied in the IIHTT, the proprietary 2-D segmentation algorithm (Zeiss Meditec [ZM] method) used in the commercial OCT device displayed noteworthy failure rates in the measurement of average RNFL thickness (10%), TRT (16%), and RGCL plus IPL thickness (20%). segmentation algorithm from the University of Iowa engineering group 5 was less prone to failure, with rates of 2.4%, 2.4%, and 0.8%, respectively for the same OCT parameters.
The IIHTT showed that acetazolamide significantly improved perimetric mean deviation (PMD), cerebrospinal fluid (CSF) pressure, quality-of-life measures, and papilledema grade in subjects with mild visual field loss in patients newly diagnosed with IIH. 2 The accepted objective method for evaluating papilledema and monitoring the alterations in the ONH, the Frisén scale, is an ordinal grading based on descriptive features. 6 Spectral-domain OCT provides continuous variable measurements that demonstrate the structural changes in the optic nerve and retina because of papilledema and measures the effects of intracranial hypertension and its treatment.
We report the results of OCT measures for the 6-month investigational phase of the IIHTT by treatment group. We investigated: (1) whether the 3 OCT measures reflecting swellingdRNFL thickness, TRT, and ONH volumedare improved significantly with acetazolamide compared with placebo or with weight loss (see "Methods" for definition) compared with no weight loss; (2) whether these 3 OCT measures change to the same degree from baseline in study eyes at the study outcome time point of 6 months; (3) whether strong interocular correlations for these 3 OCT measures are maintained at 6 months; (4) whether the amount of swelling found with these 3 OCT measures are correlated strongly with the Frisén grade at 6 months; and (5) whether the RGCL plus IPL thins significantly over 6 months and whether RGCL plus IPL thinning correlates with vision performance at 6 months.
Methods
Details of the IIHTT study design and entry criteria are published. 7 Patients with IIH who were naïve to treatment with a PMD of À2.00 to À7.00 dB using the Swedish interactive threshold algorithm standard 24-2 test pattern on the Humphrey Field Analyzer II perimeter (Carl Zeiss Meditec, Inc, Dublin, CA) in the eye with the worse PMD (designated the study eye) were enrolled. All subjects signed consent and the study was performed under institutional review board approval and in accordance with the Declaration of Helsinki. The trial is registered at ClinicalTrials.gov (identifier, NCT01003639).
Standardized fundus photographs, Frisén grading of photographs at the photographic reading center 8 and by clinical examination by site investigators, high-and low-contrast (2.5%) visual acuity, threshold 24-2 perimetry, and SD OCT imaging using the Cirrus 4000 SD OCT device (with version 6.01 software; Carl Zeiss Meditec, Inc) were performed in each eye at each visit. Study sites followed a study-specific protocol for image collection by certified technicians, digitally transferred the collected data, and had quality control and analyses by the OCT reading center. The availability of the specific study OCT limited the substudy to subjects at 24 sites.
The image acquisition protocol required 2 optic disc regions centered on the optic disc and 2 macular region volume scans centered on the fovea. The OCT data were uploaded to the NORDIC imaging center site via a secure upload web client. In addition to certifying site equipment and technicians, the OCT reading center maintained quality control on all OCT data collected. 1 We used optic disc region volume image data to calculate the peripapillary circumference average RNFL thickness and TRT with the ZM (2-D) method and 3-D segmentation method. The ONH volume was calculated using 3-D analysis of segmented optic disc volume scans. 5 Three-dimensional layer segmentation was performed on the ONH-centered scans, and from each ONH-centered volume, the total retinal volume (i.e., the volume between the internal limiting membrane and the retinal pigment epithelium reference surface) was computed. The RNFL thickness and TRT were computed using a radius of 1.73 mm around the center of the ONH.
Using the Macula Cube volumetric images, TRT of sectors and the average thickness of the RGCL plus IPL complex were measured using the ZM and 3-D segmentation methods. The ZM method finds the distance between the outer boundary of the RNFL and the outer boundary of the IPL to report the combined thickness of the RGCL plus IPL, while excluding the RNFL. For 3-D segmentation analysis, 11 intraretinal surfaces of each macula-centered volumetric scan were segmented first using the graph-theoretic approach developed at the University of Iowa. 5 The (1) internal limiting membrane, (2) interface between the RNFL and the RGCL, (3) interface between the IPL and the inner nuclear layer, and (4) posterior surface of the retinal pigment epithelial layer surfaces were retained to enable computation of the fovea center and RGCL plus IPL thickness. For each A-scan location, the RGCL plus IPL thickness was defined as the distance between the second surface and the third surface.
Statistical Analyses
For 3-D segmentation RGCL plus IPL thickness, age-matched controls (derived by 3-D segmentation of the set of normative scans provided by Carl Zeiss Meditec, Inc) were used to determine the average RGCL as a percentile of the controls. Descriptive statistics were used to summarize each SD OCT measure based on the first measurement of the study eye (the eye with worse PMD). The first SD OCT measures from both eyes were compared using Pearson correlation coefficients to describe the interocular relationship of these measures (each comparison was for the same measure and method of analysis performed in both eyes).
The RGCL plus IPL value calculated by 3-D segmentation was defined as thinned if the study eye RGCL plus IPL value was less than the fifth percentile of the 3-D segmentation RGCL value derived from age-matched Zeiss normative scans. We used t tests to compare this group with study subjects with RGCL plus IPL thickness values in the fifth percentile or more of controls.
The IIH clinical characteristics, collected at 6 months under the IIHTT protocol, were compared with the 6-month OCT findings. Frisén grade of papilledema was determined from digital photographs evaluated by the photographic reading center and also by clinical examination (not by photographic review at the site) performed by the principle investigator at each site. Specific IIH clinical features that were correlated with the OCT findings included amount of weight change, body mass index (BMI), and CSF opening pressure in millimeters of oxygen at 6 months. The best-corrected visual acuity (reported as number of letters correctly identified) for high-contrast (100%) and low-contrast (2.5%) charts and PMD (reported in decibels) on automated threshold visual field testing were correlated with the OCT findings. All OCT data were evaluated and compared for treatment group assignment (acetazolamide plus weight management [acetazolamide-treated group] and placebo plus weight management [placebo-treated group]) and whether the planned weight loss target (defined as 6% of the weight at study entry) was reached at 6 months (weight loss or no weight loss).
We also analyzed the OCT data for IIHTT treatment failures. Treatment failure was defined when a participant with baseline PMD up to À3.5 dB had visual function worsen by more than 2 dB PMD from baseline in either eye, or when a participant with baseline PMD between À3.5 dB and À7 dB had visual function worsen by more than 3 dB PMD from baseline in either eye. An adjudication committee, using all available clinical information, confirmed that the worsening was the result of progression of IIH. 7 We explored whether these eyes had baseline OCT features predictive of failure or subsequent OCT features that correlated with visual field worsening.
Mean responses for each OCT variable and interocular correlations were computed using repeated-measures analysis of covariance models that included treatment group as the factor of interest with adjustment for site and the baseline value of the outcome. Months 3 and 6 were treated as categorical variables. The interactions between treatment group (acetazolamide or placebo) and month and between baseline value of the outcome and month also were included in the models. Treatment effects were the group differences (acetazolamide vs. placebo) in adjusted mean response. Weight change effects were reported as the group differences (loss vs. no change) in adjusted mean response. The covariance structure of the R matrix was specified as direct product compound symmetry.
Results
Eighty-nine (43 acetazolamide treated, 46 placebo treated) of 165 enrolled IIHTT subjects were included in the OCT substudy. At study entry, all the OCT measures reflecting swelling associated with papilledema, RNFL thickness, TRT, and ONH volume were similar in study eyes of both treatment groups (Figs 1, 2, and 3; all baseline data reported previously 1 ). Over 6 months, all 3 OCT measures were reduced in study eyes in both treatment groups, with significant changes seen by 3 months (Figs 1e3). The changes from baseline at 6 months for ONH volume and the RNFL thickness and TRT measured by both methods for study eyes showed strong correlation with the fellow nonstudy eye and for nonstudy eyes that met criteria for study entry ( Table 1 ). The RGCL plus IPL thickness was reduced minimally at 6 months. The correlations were strong for 3-D segmentation-derived RGCL thickness, but not for values derived from the ZM method (Table 1 ; see "Discussion").
At 6 months, the acetazolamide-treated study eyes demonstrated 3-D segmentation-derived mean RNFL thickness (174 mm; P ¼ 0.001), TRT (218 mm; P ¼ 0.001), and ONH volume (4.9 mm 3 ; P ¼ 0.001) that were less than eyes in the placebo group eyes (93 mm, 121 mm, 2.4 mm 3 , respectively; Figs 1e3). Similar results were seen in nonstudy eyes (data not shown). The mean reduction in the RNFL thickness, TRT, and ONH volume compared with study entry was significantly greater in the acetazolamide-treated Figure 1 . Boxplots showing average retinal nerve fiber layer (RNFL) thickness at study enrollment (month 0), month 3, and month 6, divided by treatment group. Acetazolamide (ACZ; solid) and placebo (Pbo; hashed) boxes for each time point for 3-dimensional segmentation and Zeiss Meditec (ZM) algorithm show derived data. The difference from baseline to month 6 values is significant for both groups using both methods (P < 0.001 for ACZ and P ¼ 0.001 for Pbo). study eyes ( Table 2 ). The RNFL thickness (P ¼ 0.01), TRT (P ¼ 0.003), and ONH volume (P ¼ 0.002) showed greater reduction in subjects who lost weight compared with those who had minor or no weight loss ( Table 3 ). The reduction of OCT measurements associated with weight loss was seen in either treatment group. The differences for RNFL thickness, TRT, ONH volume, and RGCL plus IPL thickness between weight groups for acetazolamide and placebo treatment groups were similar (Table 3) .
At 6 months, the RNFL thickness, TRT, and ONH volume showed significant moderate correlations (r ¼ 0.41e0.53; P 0.0001) with Frisén grade determined by both clinical examination and photographic reading center evaluations (Table 4 ). Comparing the change in RNFL thickness, TRT, and ONH volume with a change in Frisén grade, determined by clinical examination and reading center photographs, showed slightly stronger correlations (Table 4 ). There were no correlations (data not shown) for any of the OCT measures compared with high-or low-contrast visual acuity, PMD, CSF opening pressure, or BMI (data not shown). At 6 months, RGCL thickness values derived by 3-D segmentation and ZM methods were reduced minimally for both treatment groups (Fig 4; Tables 1 and 2 ). The RGCL thickness (by 3-D segmentation) was less than the normal fifth percentile in 9 study eyes (7%) at study entry, in 14 study eyes (36%) at 3 months, and in 14 study eyes (50%) at 6 months. The PMD (P ¼ 0.001) was significantly worse in eyes with less than fifth-percentile RGCL thickness at 6 months; however, high-contrast visual acuity (P ¼ 0.56) and low-contrast visual acuity (P ¼ 0.12) were not significantly different at 6 months ( Table 5 ). The PMD and highand low-contrast visual acuity were not significantly different between eyes grouped by RGCL thickness at 3 months ( Table 5 ). The 10 study eyes with RNFL thickness less than the fifth percentile (83 mm) at 6 months did not have worse PMD or high-or lowcontrast visual acuity (data not shown).
At 6 months, 19 eyes had RNFL thickness less than the normal ZM fifth-percentile thickness (83 mm), 8 of which also had 3-D segmentation RGCL thickness values less than the normal ZM fifth-percentile values. These 19 eyes did not have significantly worse PMD, high-contrast visual acuity, or low-contrast visual acuity than eyes without RNFL thinning (data not shown). Six of the 7 eyes that met criteria for treatment failure had OCT data collected. Only 1 of 6 eyes that had visual field loss leading to treatment failure had RGCL plus IPL thickness (65.4 mm) that was less than the fifth percentile at study entry, and treatment failed in this patient at 1 month. No other eyes had major RGCL reduction before or at the time of treatment failure. None of the treatment failure eyes demonstrated RNFL thinning less than the control fifth percentile at the time of failure. Optical coherence tomography data collection was not consistent after treatment failure. 
Discussion
Our results, collected in this longitudinal prospective study and treatment trial of IIH patients using SD OCT to monitor the effects of papilledema, showed that acetazolamide plus weight management was effective in reducing swelling of RNFL, total retina, and ONH volume in study and nonstudy eyes at 6 months in the IIHTT. These OCT measures also were reduced in the placebo plus weight management group. Eyes of subjects with at least 6% of baseline body weight reduction (IIHTT planned target) showed significantly less swelling of OCT measures as well, regardless of the treatment group. Thinning or atrophy of the macula region RGCL was negligible in most study and nonstudy eyes. The RNFL and TRT thicknesses and ONH volume measurements had similar sensitivity for following the effects of papilledema and the change with treatment. This differs from prior reports of Scott et al 10 and Vartin et al 11 suggesting the TRT was superior to RNFL thickness for monitoring papilledema. Our use of 3-D segmentation probably increased the reliability as well as the ability to actually measure the swelling when severe.
There was no overall correlation with the average RNFL or RGCL thickness and visual performance at 6 months. However, even when excluding the treatment failure eyes (6 eyes in the OCT cohort), loss or thinning of the RGCL to less than the control fifth percentile at 6 months was correlated significantly with mild, but definitely worse, PMD. Also, eyes with RNFL thinning did not demonstrate significantly worse visual performance than eyes with continued RNFL swelling or normal thickness. In IIH, where continued papilledema can obscure OCT demonstration of RNFL thinning or atrophy, RGCL thickness measurement with 3-D segmentation, in contrast to 2-D methods, 1 is a reliable structural biomarker of neuronal loss. We cannot explain why the RGCL thickness was minimally reduced at 6 months in the acetazolamide treatment group. This is difficult to reconcile given the better visual field PMD at 6 months in both treatment groups that was significantly better in the entire IIHTT cohort acetazolamidetreated eyes as reported in the primary outcome article. 2 It may be that the baseline RGCL plus IPL slight increase in thickness in the acetazolamide group (see Fig 4) was the result of retinal edema or some other cause of retinal swelling that resolved. Nevertheless, the amount of RGCL thinning at 6 months was nominal compared with RGCL thinning because of other optic neuropathies (Wang J-K, et al. IOVS 2014; 515 :ARVO E-Abstract 5780-B0116). Additionally, we believe the lack of interocular correlation for change in RGCL thickness for the ZM method (2-D segmentation) was the result of the algorithm failure causing artificially low values at baseline. 1 We were not surprised to see a weaker correlation than was seen at baseline 3 between the OCT measures of peripapillary retina and ONH swelling and Frisén grade at 6 months. Given that 52% of placebo-treated eyes and 75% of acetazolamide-treated eyes were either grade 0 or 1, we anticipated a floor effect as the continuous variable RNFL thickness, TRT, and ONH volume values became less swollen. Additionally, OCT and Frisén grading assess different pathophysiological aspects of papilledema. The Frisén grade is based on descriptive inspection of numerous features that are grouped into set stages. Determining progression or regression of edema can be obscured by gliosis, ischemia, and dilated venules. In contrast, the OCT evaluated with 3-D segmentation provides continuous reliable measures that seem to reflect the effects of intracellular and extracellular edema and axonal loss and thinning across all degrees of swelling. Frisén grade changes over time or in response to therapy can show large changes, 12 but judging grade changes when modest amounts of swelling are present is difficult.
The absolute values or change from baseline for RNFL thickness, TRT, ONH volume, or RGCL plus IPL thickness at 6 months did not change with the clinical features relevant to IIH, which included high-or low-contrast visual acuity, PMD, CSF opening pressure, or the BMI at 6 months. This is similar to the findings of Skau et al, 13 who showed that the CSF pressure did not correlate with the OCT in 20 patients followed up for less than 1 month and approximately 5 years. Our results differed with those of Skau et al 13 and Rebolleda and MunozNegrete, 14 who showed that OCT swelling frequently resolves over months. In contrast, IIHTT eyes showed persistent, albeit reduced, OCT-measured peripapillary and ONH swelling in many eyes during the uniform 6-month follow-up.
The benefits of acetazolamide and weight loss on OCT swelling reduction could not be separated easily given that acetazolamide had an effect on weight outcome. Although IIHTT subjects who achieved the weight loss goal of at least 6% of the presentation weight at 6 months had reduced swelling by OCT, there was no direct correlation with BMI decrease and a reduction in swelling of the RNFL or total retina. This is similar to a prior report that followed up patients for 3 months, 15 suggesting that small amounts of weight loss has limited benefit in IIH. However, at least 1 report using retrospective data suggested that small amounts of weight loss could reduce IIH-associated findings.
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Optical coherence tomography assessments of swelling resulting from papilledema in IIH are improved with acetazolamide plus weight management and placebo plus weight management. In contrast to the strong correlation at baseline, 6-month RNFL thickness, TRT, and ONH volume showed only moderate correlations with papilledema grade. Treated IIH with mild vision loss is associated with minimal RGCL plus IPL thinning in most eyes. Optical coherence tomography is a useful procedure to monitor the consequences of papilledema resulting from intracranial hypertension and to measure the effects of therapy. Boxplots showing average retinal ganglion cell layer (RGCL) plus inner plexiform layer (IPL) thickness at study enrollment (month 0), month 3, and month 6, divided by treatment group. Acetazolamide (ACZ; solid) and placebo (Pbo; hashed) boxes for each time point for 3-dimensional segmentation and Zeiss Meditec (ZM) algorithm show derived data. The difference from baseline to month 6 values is significant for both groups using 3-dimensional segmentation (P < 0.001 for ACZ and P ¼ 0.01 for Pbo) and significant for ACZ (P ¼ 0.03), but not for Pbo (P ¼ 0.09) for the ZM method. Note that the differences were miniscule. 
